Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Survival Curves01:18

Survival Curves

319
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
319
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

398
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
398
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

198
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
198
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

287
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
287
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

612
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
612
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

266
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
266

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.

Therapeutic advances in medical oncology·2024
Same author

The effect of body mass index at diagnosis on survival of patients with squamous cell head and neck carcinoma.

American journal of cancer research·2024
Same author

Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations.

Annals of the American Thoracic Society·2024
Same author

Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study.

Current oncology (Toronto, Ont.)·2024
Same author

Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.

Pharmacoepidemiology and drug safety·2024
Same author

A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.

Clinical lung cancer·2024

Related Experiment Video

Updated: Sep 12, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.

Yangqing Deng1, Meiling Hao2, Shao Hui Huang3

  • 1Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.

Statistics in Medicine
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

We developed Health Utility-adjusted Survival (HUS), a novel composite endpoint that enhances statistical power and efficiency for clinical trials. This method comprehensively integrates survival and health utility, outperforming traditional overall survival metrics.

Keywords:
hazard ratiohealth utilityoverall survivalproportional hazardsrandomized controlled trialstime‐to‐event data

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Related Experiment Videos

Last Updated: Sep 12, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Health Economics

Background:

  • Overall survival is the primary endpoint in many randomized trials comparing new treatments to standard care or placebo.
  • Assessing health utility as a secondary outcome in survival trials can be limited by statistical power and study design.
  • There is a need for methods that effectively integrate both survival and health utility data.

Purpose of the Study:

  • To introduce and evaluate Health Utility-adjusted Survival (HUS), a composite endpoint designed to improve statistical power and efficiency in clinical trials.
  • To develop methodological extensions of HUS to address limitations in specific scenarios.
  • To establish the asymptotic properties of HUS test statistics.

Main Methods:

  • Development of the Health Utility-adjusted Survival (HUS) composite endpoint.
  • Derivation of asymptotic distributions for HUS test statistics.
  • Conducting comprehensive simulation studies and applying HUS to retrospective patient data.

Main Results:

  • The HUS endpoint demonstrated increased statistical power and potential for reduced sample size compared to overall survival.
  • Methodological extensions were proposed and validated for HUS.
  • Simulation studies and data application confirmed the superior efficiency and feasibility of HUS.

Conclusions:

  • Health Utility-adjusted Survival (HUS) offers a more comprehensive and statistically powerful approach to evaluating treatments by integrating survival and health utility.
  • The proposed extensions enhance the applicability and performance of HUS in diverse clinical trial settings.
  • HUS represents a valuable advancement in clinical trial endpoint methodology, particularly in oncology and comparative effectiveness research.